Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-BEGIN
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 22 Feb 2022 Results of an analysis assessing, whether Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and structural damage progression in patients with rheumatoid arthritis using two phase III studies (RA-BEAM and RA-BEGIN) published in the Annals of the Rheumatic Diseases
    • 09 Nov 2021 Results of post-hoc analysis of 3 studies (RA-BEGIN (NCT01711359); RA-BEAM (NCT01710358) & RA-BEACON (NCT01721044)) assessing the relative importance of PROs on the Patient Global Assessment of Disease Activity (PtGA) and health-related quality of life (HRQoL) and whether these differ in patients with good disease control compared with those not in low disease activity (LDA) or remission in different patient populations, presented at the ACR Convergence 2021.
    • 27 Oct 2021 Results (n=3770) assessing safety of baricitinib for the treatment of rheumatoid arthritis from long-term extension study and integrated database (NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078), published in the Annals of the Rheumatic Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top